Loading…
Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
Anti-vascular effects of the novel Vinca alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation Vinca . Administration of the maximum tolerated dose...
Saved in:
| Published in: | British journal of cancer 2001, Vol.84 (2), p.290-295 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c503t-d4e2b329304ff81636bb1be43ebea701b75cb6bb2c0b188c7fda1d580fa372683 |
|---|---|
| cites | |
| container_end_page | 295 |
| container_issue | 2 |
| container_start_page | 290 |
| container_title | British journal of cancer |
| container_volume | 84 |
| creator | Holwell, S E Hill, B T Bibby, M C |
| description | Anti-vascular effects of the novel
Vinca
alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation
Vinca
. Administration of the maximum tolerated dose of either vinflunine (50 mg kg
–1
) or vinorelbine (8 mg kg
–1
) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign
http://www.bjcancer.com |
| doi_str_mv | 10.1054/bjoc.2000.1587 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70632820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-d4e2b329304ff81636bb1be43ebea701b75cb6bb2c0b188c7fda1d580fa372683</originalsourceid><addsrcrecordid>eNp1kc-LEzEUx4Mobrd69aYEBW_TzY-ZZOYilOLqwooX9RqSzMtuykxSk5mC_72pLV1d8BRe3ud98335IvSKkhUlTX1lttGuGCGlbFr5BC1ow1lFWyafokW5lhXpGLlAlzlvS9mRVj5HF5RSQXlHFujHOky-2uts50EnDM6BnTKODu99cMMcfADsA57uAX9ZbzBt1nhKOuTdoMOkzQBY9xCi1cn6EEeNx9jD8AI9c3rI8PJ0LtH364_fNp-r26-fbjbr28o2hE9VXwMznHWc1M61VHBhDDVQczCgJaFGNtaUO2aJoW1rpes17ZuWOM0lEy1fog9H3d1sRugthGJuULvkR51-qai9-rcT_L26i3vFuOCS8CLw_iSQ4s8Z8qRGny0MZTuIc1aSCM5aRgr49hG4jXMKZTnFWNcJ2TBZoNURsinmnMCdnVCiDnmpQ17qkJc65FUG3vzt_wE_BVSAdyegRKQHV77e-nzmOkrq4nCJro5ULo1wB-nB3H8ffn2cCHqaE5wFhej-9H8DTA23qQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229967527</pqid></control><display><type>article</type><title>Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model</title><source>PubMed Central Free</source><creator>Holwell, S E ; Hill, B T ; Bibby, M C</creator><creatorcontrib>Holwell, S E ; Hill, B T ; Bibby, M C</creatorcontrib><description>Anti-vascular effects of the novel
Vinca
alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation
Vinca
. Administration of the maximum tolerated dose of either vinflunine (50 mg kg
–1
) or vinorelbine (8 mg kg
–1
) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign
http://www.bjcancer.com</description><identifier>ISSN: 0007-0920</identifier><identifier>ISSN: 1532-1827</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.2000.1587</identifier><identifier>PMID: 11161390</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adenocarcinoma - pathology ; Adenocarcinoma - prevention & control ; Angiogenesis Inhibitors - pharmacology ; Animals ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cancer therapies ; Chemotherapy ; Cocoa ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Drug dosages ; Drug Resistance ; Endothelium, Vascular - cytology ; Endothelium, Vascular - drug effects ; Epidemiology ; Humans ; Male ; Medical research ; Medical sciences ; Mice ; Mice, Inbred Strains ; Molecular Medicine ; Neoplasm Transplantation ; Neoplasms, Experimental - pathology ; Neoplasms, Experimental - prevention & control ; Neovascularization, Pathologic - prevention & control ; Oncology ; Pharmacology. Drug treatments ; Regular ; regular-article ; Time Factors ; Tumor Cells, Cultured ; Tumors ; Umbilical Veins ; Vinblastine - analogs & derivatives ; Vinblastine - pharmacology ; Vincristine - pharmacology</subject><ispartof>British journal of cancer, 2001, Vol.84 (2), p.290-295</ispartof><rights>The Author(s) 2001</rights><rights>2001 INIST-CNRS</rights><rights>Copyright 2001 Cancer Research Campaign.</rights><rights>Copyright Nature Publishing Group Jan 2001</rights><rights>Copyright © 2001 Cancer Research Campaign 2001 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-d4e2b329304ff81636bb1be43ebea701b75cb6bb2c0b188c7fda1d580fa372683</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363703/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363703/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=910406$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11161390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holwell, S E</creatorcontrib><creatorcontrib>Hill, B T</creatorcontrib><creatorcontrib>Bibby, M C</creatorcontrib><title>Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Anti-vascular effects of the novel
Vinca
alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation
Vinca
. Administration of the maximum tolerated dose of either vinflunine (50 mg kg
–1
) or vinorelbine (8 mg kg
–1
) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign
http://www.bjcancer.com</description><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - prevention & control</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cocoa</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug dosages</subject><subject>Drug Resistance</subject><subject>Endothelium, Vascular - cytology</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Molecular Medicine</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasms, Experimental - pathology</subject><subject>Neoplasms, Experimental - prevention & control</subject><subject>Neovascularization, Pathologic - prevention & control</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Regular</subject><subject>regular-article</subject><subject>Time Factors</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><subject>Umbilical Veins</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vinblastine - pharmacology</subject><subject>Vincristine - pharmacology</subject><issn>0007-0920</issn><issn>1532-1827</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNp1kc-LEzEUx4Mobrd69aYEBW_TzY-ZZOYilOLqwooX9RqSzMtuykxSk5mC_72pLV1d8BRe3ud98335IvSKkhUlTX1lttGuGCGlbFr5BC1ow1lFWyafokW5lhXpGLlAlzlvS9mRVj5HF5RSQXlHFujHOky-2uts50EnDM6BnTKODu99cMMcfADsA57uAX9ZbzBt1nhKOuTdoMOkzQBY9xCi1cn6EEeNx9jD8AI9c3rI8PJ0LtH364_fNp-r26-fbjbr28o2hE9VXwMznHWc1M61VHBhDDVQczCgJaFGNtaUO2aJoW1rpes17ZuWOM0lEy1fog9H3d1sRugthGJuULvkR51-qai9-rcT_L26i3vFuOCS8CLw_iSQ4s8Z8qRGny0MZTuIc1aSCM5aRgr49hG4jXMKZTnFWNcJ2TBZoNURsinmnMCdnVCiDnmpQ17qkJc65FUG3vzt_wE_BVSAdyegRKQHV77e-nzmOkrq4nCJro5ULo1wB-nB3H8ffn2cCHqaE5wFhej-9H8DTA23qQ</recordid><startdate>2001</startdate><enddate>2001</enddate><creator>Holwell, S E</creator><creator>Hill, B T</creator><creator>Bibby, M C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2001</creationdate><title>Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model</title><author>Holwell, S E ; Hill, B T ; Bibby, M C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-d4e2b329304ff81636bb1be43ebea701b75cb6bb2c0b188c7fda1d580fa372683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - prevention & control</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cocoa</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug dosages</topic><topic>Drug Resistance</topic><topic>Endothelium, Vascular - cytology</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Molecular Medicine</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasms, Experimental - pathology</topic><topic>Neoplasms, Experimental - prevention & control</topic><topic>Neovascularization, Pathologic - prevention & control</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Regular</topic><topic>regular-article</topic><topic>Time Factors</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><topic>Umbilical Veins</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vinblastine - pharmacology</topic><topic>Vincristine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holwell, S E</creatorcontrib><creatorcontrib>Hill, B T</creatorcontrib><creatorcontrib>Bibby, M C</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holwell, S E</au><au>Hill, B T</au><au>Bibby, M C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2001</date><risdate>2001</risdate><volume>84</volume><issue>2</issue><spage>290</spage><epage>295</epage><pages>290-295</pages><issn>0007-0920</issn><issn>1532-1827</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Anti-vascular effects of the novel
Vinca
alkaloid, vinflunine have been investigated in the MAC 15A transplantable murine colon adenocarcinoma model and compared with those induced by the most recently identified clinically useful third generation
Vinca
. Administration of the maximum tolerated dose of either vinflunine (50 mg kg
–1
) or vinorelbine (8 mg kg
–1
) resulted in significant tumour growth delay with subsequent histological analysis revealing substantial haemorrhagic necrosis. This suggested possible anti-vascular effects and these were confirmed by Hoechst 33342 perfusion studies. Vinflunine, currently undergoing Phase I trials in Europe, was found to be at least as effective as the clinically active vincristine and vinorelbine in this model and, remarkably, produced anti-vascular effects at doses much lower than the maximum tolerated dose. Although vinflunine caused apoptosis in HUVEC monolayer cultures this event did not occur within the first 8 hours of exposure whereas vascular shutdown in vivo was observed within the first 4 hours. © 2001 Cancer Research Campaign
http://www.bjcancer.com</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11161390</pmid><doi>10.1054/bjoc.2000.1587</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2001, Vol.84 (2), p.290-295 |
| issn | 0007-0920 1532-1827 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363703 |
| source | PubMed Central Free |
| subjects | Adenocarcinoma - pathology Adenocarcinoma - prevention & control Angiogenesis Inhibitors - pharmacology Animals Antineoplastic agents Antineoplastic Agents, Phytogenic - pharmacology Apoptosis - drug effects Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Chemotherapy Cocoa Disease Models, Animal Dose-Response Relationship, Drug Drug dosages Drug Resistance Endothelium, Vascular - cytology Endothelium, Vascular - drug effects Epidemiology Humans Male Medical research Medical sciences Mice Mice, Inbred Strains Molecular Medicine Neoplasm Transplantation Neoplasms, Experimental - pathology Neoplasms, Experimental - prevention & control Neovascularization, Pathologic - prevention & control Oncology Pharmacology. Drug treatments Regular regular-article Time Factors Tumor Cells, Cultured Tumors Umbilical Veins Vinblastine - analogs & derivatives Vinblastine - pharmacology Vincristine - pharmacology |
| title | Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T19%3A18%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-vascular%20effects%20of%20vinflunine%20in%20the%20MAC%2015A%20transplantable%20adenocarcinoma%20model&rft.jtitle=British%20journal%20of%20cancer&rft.au=Holwell,%20S%20E&rft.date=2001&rft.volume=84&rft.issue=2&rft.spage=290&rft.epage=295&rft.pages=290-295&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.2000.1587&rft_dat=%3Cproquest_pubme%3E70632820%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-d4e2b329304ff81636bb1be43ebea701b75cb6bb2c0b188c7fda1d580fa372683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=229967527&rft_id=info:pmid/11161390&rfr_iscdi=true |